Education
About Us
Working with TipRanks
Follow Us
Dawnrays Pharmaceutical Holdings Ltd. (HK:2348)
:2348
RESEARCH TOOLSreports
2348 Stock Chart & Stats
Day’s Range― - ―
52-Week RangeHK$1.07 - HK$1.40
Previous CloseN/A
Volume344.00K
Average Volume (3M)259.33K
Market Cap
HK$1.88B
Enterprise ValueHK$956.61M
Total Cash (Recent Filing)HK$1.37B
Total Debt (Recent Filing)¥34.72M
Price to Earnings (P/E)3.1
Beta0.28
Next Earnings
Aug 22, 2025EPS EstimateN/A
Last Dividend Ex-Date
May 27, 2025Dividend Yield4.8%
Share Statistics
EPS (TTM)0.41
Shares Outstanding1,502,885,000
10 Day Avg. Volume305,600
30 Day Avg. Volume259,333
Financial Highlights & Ratios
PEG Ratio0.00
Price to Book (P/B)0.67
Price to Sales (P/S)0.00
P/FCF Ratio7.65
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
Dawnrays Pharmaceutical Holdings Ltd. News
PremiumCompany Announcements
Dawnrays Pharmaceutical Successfully Passes All AGM Resolutions
PremiumCompany Announcements
Dawnrays Pharmaceutical Announces 2025 AGM and Key Resolutions
PremiumCompany Announcements
Dawnrays Pharmaceutical Declares Special Dividend for 2024
PremiumCompany Announcements
Dawnrays Pharmaceutical Declares Final Dividend for 2024Options Prices
Currently, No data available
---
Ownership Overview
―
Insiders
4.96%
Mutual Funds
― Other Institutional Investors
95.04% Public Companies and
Individual Investors
2348 FAQ
What was Dawnrays Pharmaceutical Holdings Ltd.’s price range in the past 12 months?
Dawnrays Pharmaceutical Holdings Ltd. lowest stock price was HK$1.07 and its highest was HK$1.40 in the past 12 months.
What is Dawnrays Pharmaceutical Holdings Ltd.’s market cap?
Dawnrays Pharmaceutical Holdings Ltd.’s market cap is HK$1.88B.
When is Dawnrays Pharmaceutical Holdings Ltd.’s upcoming earnings report date?
Dawnrays Pharmaceutical Holdings Ltd.’s upcoming earnings report date is Aug 22, 2025 which is in 69 days.
How were Dawnrays Pharmaceutical Holdings Ltd.’s earnings last quarter?
Dawnrays Pharmaceutical Holdings Ltd. released its earnings results on Mar 28, 2025. The company reported HK$0.052 earnings per share for the quarter, beating the consensus estimate of N/A by HK$0.052.
Is Dawnrays Pharmaceutical Holdings Ltd. overvalued?
According to Wall Street analysts Dawnrays Pharmaceutical Holdings Ltd.’s price is currently Overvalued.
Does Dawnrays Pharmaceutical Holdings Ltd. pay dividends?
Dawnrays Pharmaceutical Holdings Ltd. pays a Annually dividend of HK$0.048 which represents an annual dividend yield of 4.8%. See more information on Dawnrays Pharmaceutical Holdings Ltd. dividends here
What is Dawnrays Pharmaceutical Holdings Ltd.’s EPS estimate?
Dawnrays Pharmaceutical Holdings Ltd.’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Dawnrays Pharmaceutical Holdings Ltd. have?
Dawnrays Pharmaceutical Holdings Ltd. has 1,502,885,000 shares outstanding.
What happened to Dawnrays Pharmaceutical Holdings Ltd.’s price movement after its last earnings report?
Dawnrays Pharmaceutical Holdings Ltd. reported an EPS of HK$0.052 in its last earnings report, beating expectations of N/A. Following the earnings report the stock price went down -2.542%.
Which hedge fund is a major shareholder of Dawnrays Pharmaceutical Holdings Ltd.?
Currently, no hedge funds are holding shares in HK:2348
Dawnrays Pharmaceutical Holdings Ltd. Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Technicals
SMA
Positive
20 days / 200 days
Momentum
16.06%
12-Months-Change
Fundamentals
Return on Equity
18.33%
Trailing 12-Months
Asset Growth
6.97%
Trailing 12-Months
Company Description
Dawnrays Pharmaceutical Holdings Ltd.
Dawnrays Pharmaceutical Holdings Ltd. (2348) is a pharmaceutical company based in China, engaged in the research, development, manufacture, and sale of generic drugs and active pharmaceutical ingredients (APIs). The company's core products include a wide range of antibiotics, cardiovascular system drugs, and diabetes medications. Dawnrays focuses on providing affordable and high-quality pharmaceutical products to meet the healthcare needs of patients globally.
Technical Analysis
3SBio
―
Sino Biopharmaceutical
―
China Resources Pharmaceutical Group Ltd.
―
Livzon Pharmaceutical Group
―
CSPC Pharmaceutical Group
―